C83.3
Conditions
Interventions
Group 1: 1. Data documentation at baseline:
- Informed consent
- Diagnosis and date of diagnosis, stadium according to Ann-Arbor (in case of nodal lymphoma)
- Demographic data including year of
Sponsors
Universitätsklinik für Hämatologie und Onkologie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Immunocompetent patients with newly diagnosed PZNSL =18 years - Histologically confirmed diagnosis of DLBCL according to WHO by a local pathologist - Chemotherapy-eligible patients 2. Immunocompetent patients with newly diagnosed nodal DLBCL =18 years of age - Histologically confirmed diagnosis of DLBCL according to WHO by a local pathologist - Chemotherapy-eligible patients 3. Healthy volunteers =18 years of age Written informed consent from patients and healthy volunteers or authorized legal carers in the event that the patient or volunteer is unable to provide information
Exclusion criteria
Exclusion criteria: ad IC 1. - Congenital or acquired immune deficiencies, including HIV infection and previous organ or stem cell transplantation - Lymphoma manifestation outside the central nervous system ad IC 2. - Congenital or acquired immune deficiencies, including HIV infection and previous organ transplants ad IC 3. - Congenital or acquired immune deficiencies, including HIV infection and previous organ or stem cell transplantation - Acute infection or illness in the last 4 weeks (e.g. heart attack, broken bone, surgery, etc.) - Known chronic infection (e.g. hepatitis B / C etc.) - Known malignancy, with the exception of one that was treated with curative intent and had no evidence of active disease for> 2 years prior to the start of the study - Known autoimmune disease - Pregnant or breastfeeding participants
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of changes in peripheral T cell counts and their subtypes during and at the end of treatment in patients with PCNSL | — |
Secondary
| Measure | Time frame |
|---|---|
| - Investigation of peripheral T cell counts and their subtypes in newly diagnosed patients with PCNSL and their correlation with prognostic factors and survival - Investigation of the correlation between the Treg number and inflammatory cytokines in peripheral blood mononuclear cells (PMNC) - Carrying out the above studies in patients with nodal DLBCL and healthy volunteers and comparing them with the results in PCNSL patients - Investigation of possible differences compared to HIV + PCNSL patients as indicated in the literature | — |
Countries
Germany
Contacts
Public ContactVanja Zeremski
Universitätsklinik für Hämatologie und Onkolgie
Outcome results
None listed